NPT
QNCX icon

Nixon Peabody Trust’s Quince Therapeutics QNCX Stock Holding History

Nixon Peabody Trust’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-56
Closed -$1.13K – 182
2026
Q1 		$1.13K Hold
56
– – ﹤0.01% 160
2025
Q4 		$37.3K Hold
56
– – ﹤0.01% 160
2025
Q3 		$18.1K Hold
56
– – ﹤0.01% 152
2025
Q2 		$18.4K Hold
56
– – ﹤0.01% 148
2025
Q1 		$14.8K Hold
56
– – ﹤0.01% 152
2024
Q4 		$20.8K Hold
56
– – ﹤0.01% 146
2024
Q3 		$8.64K Hold
56
– – ﹤0.01% 139
2024
Q2 		$8.35K Hold
56
– – ﹤0.01% 128
2024
Q1 		$11.8K Hold
56
– – ﹤0.01% 126
2023
Q4 		$11.7K Buy
+56
New +$11.2K ﹤0.01% 130

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Nixon Peabody Trust's QNCX Position: Q2 2026 in Review

Nixon Peabody Trust sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 56 shares — an estimated $1.13K sold.

Nixon Peabody Trust first reported a position in QNCX in Q4 2023 and held it in 10 quarters. The position peaked at $37.3K in Q4 2025. 26 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Nixon Peabody Trust reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Nixon Peabody Trust sold 56 Quince Therapeutics shares in Q2 2026, an estimated $1.13K.
  • Nixon Peabody Trust first reported a position in Quince Therapeutics in Q4 2023 and held it in 10 quarters.
  • Nixon Peabody Trust's Quince Therapeutics position peaked at $37.3K in Q4 2025.
  • 26 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Nixon Peabody Trust's 13F filing for Q2 2026, filed 27 Jul 2026.